دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future
Kevin L Winthrop, Richard J Whitley, Daniel Aletaha
doi : 10.1136/annrheumdis-2021-221251
Annals of the Rheumatic Diseases 2021;80:1249-1251.
Call for emergency action to limit global temperature increases, restore biodiversity and protect health
Lukoye Atwoli, Abdullah H Baqui, Thomas Benfield, Raffaella Bosurgi, Fiona Godlee, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Carlos Augusto Monteiro, Ian Norman, Kirsten Patrick, Nigel Praities, Marcel GM Olde Rikkert, Eric J Rubin, Peush Sahni, Richard Smith, Nicholas J Talley, Sue Turale, Damián Vázquez
doi : 10.1136/annrheumdis-2021-221353
Annals of the Rheumatic Diseases 2021;80:1252-1254.
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
Marcia A Friedman, Jeffrey R Curtis, Kevin L Winthrop
doi : 10.1136/annrheumdis-2021-221244
Annals of the Rheumatic Diseases 2021;80:1255-1265.
Patients with rheumatic diseases are at increased risk of infectious complications; vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs may reduce the immunogenicity of common vaccines. We will review here available data regarding the effect of these medications on influenza, pneumococcal, herpes zoster, SARS-CoV-2, hepatitis B, human papilloma virus and yellow fever vaccines. Rituximab has the most substantial impact on vaccine immunogenicity, which is most profound when vaccinations are given at shorter intervals after rituximab dosing. Methotrexate has less substantial effect but appears to adversely impact most vaccine immunogenicity. Abatacept likely decrease vaccine immunogenicity, although these studies are limited by the lack of adequate control groups. Janus kinase and tumour necrosis factor inhibitors decrease absolute antibody titres for many vaccines, but do not seem to significantly impact the proportions of patients achieving seroprotection. Other biologics (interleukin-6R (IL-6R), IL-12/IL-23 and IL-17 inhibitors) have little observed impact on vaccine immunogenicity. Data regarding the effect of these medications on the SARS-CoV-2 vaccine immunogenicity are just now emerging, and early glimpses appear similar to our experience with other vaccines. In this review, we summarise the most recent data regarding vaccine response and efficacy in this setting, particularly in light of current vaccination recommendations for immunocompromised patients.
Message from the new EULAR President and Steering Group
Annamaria Iagnocco, Daniel Aletaha, Xenofon Baraliakos, Iain B McInnes
doi : 10.1136/annrheumdis-2021-221320
Annals of the Rheumatic Diseases 2021;80:1266-1267.
The last decade witnessed the ascendancy of rheumatology to become one of the most dynamic and progressive across the fields of medicine. During the COVID-19 pandemic our discipline emerged at the forefront of molecular medicine with the rapid uptake of immune-modulatory therapeutics and depth of immune pathogenesis understanding contributing fundamentally to the COVID-19 response. The European Alliance of Associations for Rheumatology (EULAR) played a fundamental and vital role in this response in guiding rheumatic and musculoskeletal disease (RMD) therapeutics, vaccine use and even treatment innovations in the context of COVID-19 itself. Given this remarkable contribution, it is timely to reflect on EULAR—what is it and for what does it stand? At its core, EULAR represents people with RMDs, including their national societies, health professionals in rheumatology and scientific societies of rheumatology across the European nations. Our mission is to reduce the burden of RMDs on individuals and society and improve the treatment and prevention of RMDs. In this message from the new EULAR President and Steering Group, we present the most relevant activities of EULAR, its strategic aims and the concept of the EULAR family, a fantastic team of people working together across the three pillars of medical, health professional and patient societies.
Preclinical models of arthritis for studying immunotherapy and immune tolerance
Gavin R Meehan, Ranjeny Thomas, Shaima Al Khabouri, Pascale Wehr, Catharien MU Hilkens, David C Wraith, Daniela Sieghart, Michael Bonelli, György Nagy, Paul Garside, David F Tough, Huw D Lewis, James M Brewer
doi : 10.1136/annrheumdis-2021-220043
Annals of the Rheumatic Diseases 2021;80:1268-1277.
Increasingly earlier identification of individuals at high risk of rheumatoid arthritis (RA) (eg, with autoantibodies and mild symptoms) improves the feasibility of preventing or curing disease. The use of antigen-specific immunotherapies to reinstate immunological self-tolerance represent a highly attractive strategy due to their potential to induce disease resolution, in contrast to existing approaches that require long-term treatment of underlying symptoms.
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
Elena Nikiphorou, Eduardo José Ferreira Santos, Andrea Marques, Peter Böhm, Johannes WJ Bijlsma, Claire Immediato Daien, Bente Appel Esbensen, Ricardo J O Ferreira, George E Fragoulis, Pat Holmes, Hayley McBain, George S Metsios, Rikke Helene Moe, Tanja A Stamm, Annette de Thurah, Condruta Zabalan, Loreto Carmona, Ailsa Bosworth
doi : 10.1136/annrheumdis-2021-220249
Annals of the Rheumatic Diseases 2021;80:1278-1285.
An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ability to deal effectively with the practical, physical and psychological impacts of it. Self-management skills can be helpful in this regard.
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
Kulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, Deshire Alpizar Rodriguez, Anca Irinel Catrina, Juan D Cañete, Andrew P Cope, Claire Immediato Daien, Kevin D Deane, Hani El Gabalawy, Axel Finckh, V Michael Holers, Marios Koloumas, Francesca Ometto, Karim Raza, Condruta Zabalan, Annette van der Helm-van Mil, Dirkjan van Schaardenburg, Daniel Aletaha, Paul Emery
doi : 10.1136/annrheumdis-2021-220884
Annals of the Rheumatic Diseases 2021;80:1286-1298.
Despite growing interest, there is no guidance or consensus on how to conduct clinical trials and observational studies in populations at risk of rheumatoid arthritis (RA).
EULAR recommendations for intra-articular therapies
Jacqueline Uson, Sebastián Cruz Rodriguez-García, Raul Castellanos-Moreira, Terence W O'Neill, Michael Doherty, Mikael Boesen, Hemant Pandit, Ingrid Möller Parera, Valentina Vardanyan, Lene Terslev, Willm Uwe Kampen, Maria-Antonietta D'Agostino, Francis Berenbaum, Elena Nikiphorou, Irene A Pitsillidou, Jenny de la Torre-Aboki, Loreto Carmona, Esperanza Naredo
doi : 10.1136/annrheumdis-2021-220266
Annals of the Rheumatic Diseases 2021;80:1299-1305.
To establish evidence-based recommendations to guide health professionals using intra-articular therapies (IAT) in adult patients with peripheral arthropathies.
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
Ulf M Geisen, Dennis K Berner, Florian Tran, Melike Sümbül, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann C Longardt, Jeanette Franzenburg, Paula Hoff, Jan H Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert DH Markewitz, Peter J Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F Hoyer
doi : 10.1136/annrheumdis-2021-220272
Annals of the Rheumatic Diseases 2021;80:1306-1311.
In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are prioritised for vaccination. However, data concerning generation of protective antibody titres in immunosuppressed patients are scarce. Additionally, mRNA vaccines represent a new vaccine technology leading to increased insecurity especially in patients with CID.
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
David Simon, Koray Tascilar, Filippo Fagni, Gerhard Krönke, Arnd Kleyer, Christine Meder, Raja Atreya, Moritz Leppkes, Andreas E Kremer, Andreas Ramming, Milena L Pachowsky, Florian Schuch, Monika Ronneberger, Stefan Kleinert, Axel J Hueber, Karin Manger, Bernhard Manger, Carola Berking, Michael Sticherling, Markus F Neurath, Georg Schett
doi : 10.1136/annrheumdis-2021-220461
Annals of the Rheumatic Diseases 2021;80:1312-1316.
To better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs).
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun, Doron Markovits, Samy Giryes, Kohava Toledano, Yonit Tavor, Katya Dolnikov, Alexandra Balbir-Gurman
doi : 10.1136/annrheumdis-2021-220503
Annals of the Rheumatic Diseases 2021;80:1317-1321.
The registration trials of messenger RNA (mRNA) vaccines against SARS-CoV-2 did not address patients with inflammatory rheumatic diseases (IRD).
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, Paul Martin, Tina Thomson, Paul Randell, Anand Shah, Aran Singanayagam, Liz Lightstone, Alison Cox, Peter Kelleher, Michelle Willicombe, Stephen P McAdoo
doi : 10.1136/annrheumdis-2021-220626
Annals of the Rheumatic Diseases 2021;80:1322-1329.
There is an urgent need to assess the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination.
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Roni Meidan, Adi Broyde, Ari Polachek, Jonathan Wollman, Ira Litinsky, Katya Meridor, Hila Nochomovitz, Adi Silberman, Dana Rosenberg, Joy Feld, Amir Haddad, Tal Gazzit, Muna Elias, Nizar Higazi, Fadi Kharouf, Gabi Shefer, Orly Sharon, Sara Pel, Sharon Nevo, Ori Elkayam
doi : 10.1136/annrheumdis-2021-220647
Annals of the Rheumatic Diseases 2021;80:1330-1338.
Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Rebecca H Haberman, Ramin Herati, David Simon, Marie Samanovic, Rebecca B Blank, Michael Tuen, Sergei B Koralov, Raja Atreya, Koray Tascilar, Joseph R Allen, Rochelle Castillo, Amber R Cornelius, Paula Rackoff, Gary Solomon, Samrachana Adhikari, Natalie Azar, Pamela Rosenthal, Peter Izmirly, Jonathan Samuels, Brian Golden, Soumya M Reddy, Markus F Neurath, Steven B Abramson, Georg Schett, Mark J Mulligan, Jose U Scher
doi : 10.1136/annrheumdis-2021-220597
Annals of the Rheumatic Diseases 2021;80:1339-1344.
To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment.
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Marianne Graninger, Helga Radner, Daniela Sieghart, Philipp Hofer, Thomas Perkmann, Helmuth Haslacher, Renate Thalhammer, Stefan Winkler, Stephan Blüml, Karin Stiasny, Judith H Aberle, Josef S Smolen, Leonhard X Heinz, Daniel Aletaha, Michael Bonelli
doi : 10.1136/annrheumdis-2021-220781
Annals of the Rheumatic Diseases 2021;80:1345-1350.
Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-CoV-2 after immunisation.
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
Jake A Ruddy, Caoilfhionn Marie Connolly, Brian J Boyarsky, William A Werbel, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, Dorry L Segev, Julie J Paik
doi : 10.1136/annrheumdis-2021-220656
Annals of the Rheumatic Diseases 2021;80:1351-1352.
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
Medha Barbhaiya, Jonah M. Levine, Vivian P. Bykerk, Deanna Jannat-Khah, Lisa A. Mandl
doi : 10.1136/annrheumdis-2021-220732
Annals of the Rheumatic Diseases 2021;80:1352-
SARS-COV-2 vaccination after stem cell transplantation for scleroderma
Doron Rimar, Gleb slobodin, Alona Paz, Israel Henig, Tsila Zuckerman
doi : 10.1136/annrheumdis-2021-220677
Annals of the Rheumatic Diseases 2021;80:1354-1355.
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
Michael Markus Bonelli, Daniel Mrak, Thomas Perkmann, Helmuth Haslacher, Daniel Aletaha
doi : 10.1136/annrheumdis-2021-220408
Annals of the Rheumatic Diseases 2021;80:1355-1356.
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Robert Spiera, Sarah Jinich, Deanna Jannat-Khah
doi : 10.1136/annrheumdis-2021-220604
Annals of the Rheumatic Diseases 2021;80:1357-1359.
Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report
Basil Golding, Youri Lee, Hana Golding, Surender Khurana
doi : 10.1136/annrheumdis-2021-220993
Annals of the Rheumatic Diseases 2021;80:1359-1361.
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response
Fredrik N Albach, Gerd R Burmester, Robert Biesen
doi : 10.1136/annrheumdis-2021-220834
Annals of the Rheumatic Diseases 2021;80:1361-1362.
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation
Marlou T H F Janssen, Sofia Ramiro, Robert B M Landewé, César Magro-Checa, Rémy L M Mostard
doi : 10.1136/annrheumdis-2021-220040
Annals of the Rheumatic Diseases 2021;80:1362-1363.
Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs
Lotte van Ouwerkerk, Andrea E van der Meulen-de Jong, Maarten K Ninaber, Y K Onno Teng, Tom WJ Huizinga, Cornelia F Allaart
doi : 10.1136/annrheumdis-2021-219958
Annals of the Rheumatic Diseases 2021;80:1364-1365.
Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, Allan Massie, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, Dorry L Segev, Julie J Paik
doi : 10.1136/annrheumdis-2021-221145
Annals of the Rheumatic Diseases 2021;80:1365-1366.
Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’
Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, Sara Monti, Paolo Delvino, Carlomaurizio Montecucco
doi : 10.1136/annrheumdis-2021-220541
Annals of the Rheumatic Diseases 2021;80:e156.
Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al
Johannes W J Bijlsma
doi : 10.1136/annrheumdis-2021-220564
Annals of the Rheumatic Diseases 2021;80:e157.
Correspondence on ‘Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Chiara Salviani, Francesco Scolari, Federico Alberici
doi : 10.1136/annrheumdis-2021-220496
Annals of the Rheumatic Diseases 2021;80:e158.
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Giuseppe A Ramirez, Emanuel Della-Torre, Luca Moroni, Mona-Rita Yacoub, Lorenzo Dagna
doi : 10.1136/annrheumdis-2021-220539
Annals of the Rheumatic Diseases 2021;80:e159.
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Jesse Veenstra, Jie Wang, Kathleen McKinnon-Maksimowicz, Tingting Liu, Bobby Zuniga, Iltefat Hamzavi, Li Zhou, Qing-Sheng Mi
doi : 10.1136/annrheumdis-2021-220736
Annals of the Rheumatic Diseases 2021;80:e160.
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Larissa Valor-Méndez, Koray Tascilar, David Simon, Joerg Distler, Arnd Kleyer, Georg Schett, Juergen Rech
doi : 10.1136/annrheumdis-2021-220898
Annals of the Rheumatic Diseases 2021;80:e161.
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’
Timm H Westhoff, Felix S Seibert, Moritz Anft, Arturo Blazquez-Navarro, Sarah Skrzypczyk, Adrian Doevelaar, Bodo Hölzer, Krystallenia Paniskaki, Sebastian Dolff, Benjamin Wilde, Oliver Witzke, Juergen Braun, Ulrik Stervbo, Nina Babel
doi : 10.1136/annrheumdis-2021-220756
Annals of the Rheumatic Diseases 2021;80:e162.
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
Michael Bonelli, Daniel Aletaha
doi : 10.1136/annrheumdis-2021-220764
Annals of the Rheumatic Diseases 2021;80:e163.
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Caoilfhionn Marie Connolly, Darya Koenig, Srekar N Ravi, Antoine Azar, Sam Kant, Monika Dalal, Jessica Duchen, Philip Seo, Brendan Antiochos, Julie J Paik, Duvuru Geetha
doi : 10.1136/annrheumdis-2021-220972
Annals of the Rheumatic Diseases 2021;80:e164.
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Sarah H Chung, Mark Wener, Alison M Bays, Habib Rahbar, Chihiro Morishima, Andrew B Bryan, Susan L Fink, Seth Cohen, Nandita S Mani, Anu Chaudhary, Gregory C Gardner
doi : 10.1136/annrheumdis-2021-220957
Annals of the Rheumatic Diseases 2021;80:e165.
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response”by Bonelli et al
Maurizio Benucci, Arianna Damiani, Maria Infantino, Mariangela Manfredi, Valentina Grossi, Barbara Lari, Francesca Li Gobbi, Piercarlo Sarzi Puttini
doi : 10.1136/annrheumdis-2021-220829
Annals of the Rheumatic Diseases 2021;80:e166.
Response to: Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Michael Bonelli, Daniel Aletaha
doi : 10.1136/annrheumdis-2021-220997
Annals of the Rheumatic Diseases 2021;80:e167.
Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’
Gianluca Smerilli, Edoardo Cipolletta, Erica Moscioni, Francesca Francioso, Anna Maria Risa, Vincenzo Maccarrone, Davide Zompa, Andrea Di Matteo, Marco Di Carlo, Rossella De Angelis, Fausto Salaffi, Emilio Filippucci, Walter Grassi
doi : 10.1136/annrheumdis-2021-220586
Annals of the Rheumatic Diseases 2021;80:e168.
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’’ by Smerilli et al
Roberta Priori, Greta Pellegrino, Serena Colafrancesco, Cristiano Alessandri, Fulvia Ceccarelli, Manuela Di Franco, Valeria Riccieri, Rossana Scrivo, Antonio Sili Scavalli, Francesca Romana Spinelli, Fabrizio Conti
doi : 10.1136/annrheumdis-2021-220612
Annals of the Rheumatic Diseases 2021;80:e169.
Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’
Shamma Al Nokhatha, Neil MacEoin, Richard Conway
doi : 10.1136/annrheumdis-2021-219847
Annals of the Rheumatic Diseases 2021;80:e170.
Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al
Christian Dejaco, Johannes WJ Bijlsma, Frank Buttgereit
doi : 10.1136/annrheumdis-2021-219866
Annals of the Rheumatic Diseases 2021;80:e171.
